Morgan Stanley raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps an Equal Weight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer price target lowered to $26 from $27 at BofA
- Option traders moderately bearish in Pfizer with shares down 2.5%
- Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
- Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know
- Mixed options sentiment in Pfizer with shares down 1.57%